References of "Halkin, V"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEvaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign
Hanssens, L. C.; De Ceulaer, F.; Tancredi, Annalisa ULg et al

in Osteoporosis International (2004, May), 15(Suppl.1), 54

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign
Hanssens, L.; Tancredi, Annalisa ULg; DeCeulaer, F. et al

in Osteoporosis International (2004, May), 15(Suppl.1), 48-49

Detailed reference viewed: 13 (7 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign
Hanssens, L.; Tancredi, Annalisa ULg; De Ceulaer, F. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 90-91

Detailed reference viewed: 20 (7 ULg)
Full Text
Peer Reviewed
See detailEvaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign
Hanssens, L.; De Ceulaer, F.; Tancredi, Annalisa ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 90

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003?
Reginster, Jean-Yves ULg; Lecart, Marie-Paule ULg; Sarlet, Nathalie ULg et al

in Revue Médicale de Liège (2003), 58(4), 183-90

Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in ... [more ▼]

Osteoporosis in very elderly subjects is now considered, in most developed and several developing countries as a major social, clinical and financial burden. While many compounds have been investigated in the prevention or treatment of spinal fractures, few of them have unequivocally demonstrated their ability to reduce the risk of non vertebral and more specifically hip fractures in the very elderly. This situation may seem highly paradoxical since hip fractures are unanimously considered to be the most dramatic and disabling consequence of osteoporosis. The present article reviews the current evidence available to justify anti-osteoporotic medications to be recommended to very elderly subjects, in the perspective of reducing their risk of appendicular fractures. [less ▲]

Detailed reference viewed: 40 (4 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis in the very elderly
Halkin, V; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Medicographia (2002), 24(4), 316-321

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailPsychiatrie en osteoporose
Halkin, V; Reginster, Jean-Yves ULg

in Agenda Psychiatrie (L') (2000), 14

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailLes propriétés de la glucosamine
Reginster, Jean-Yves ULg; Halkin, V

in Journal de Pharmacie de Belgique (2000), 55(5), 118-121

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailEigenschappen van glucosamine
Reginster, Jean-Yves ULg; Halkin, V

in Medi-Sfeer (2000), 116

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailLe capital osseux : une épargne qui débute au berceau
Halkin, V; Reginster, Jean-Yves ULg

in L'agenda Pédiatrie (2000), 22

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailHet botkapitaal : een spaarboekje dat in de wieg begint
Halkin, V; Reginster, Jean-Yves ULg

in De Agenda Pediatrie (2000), 22

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPreventie van postmenopauzale osteoporose
Reginster, Jean-Yves ULg; Halkin, V

in De agenda Gynaecologie (2000), 19

Detailed reference viewed: 2 (1 ULg)
Peer Reviewed
See detailCalcitonine dans la prévention secondaire et tertiaire de l’ostéoporose
Halkin, V; Reginster, Jean-Yves ULg

in Medi-Sphere (1999), 3

Detailed reference viewed: 12 (2 ULg)
See detailEstablished postmenopausal osteoporosis – Assessment of treatment options
Reginster, Jean-Yves ULg; Halkin, V.; Fraikin, G. et al

in Menopause Review (1999), 1(IV), 39-55

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of Osteoporosis: Role of Bone-Forming Agents
Reginster, Jean-Yves ULg; Halkin, V.; Henrotin, Yves ULg et al

in Osteoporosis International (1999), 9 Suppl 2

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis
Halkin, V; Reginster, Jean-Yves ULg

in BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals & Gene Therapy (1998), 10(4), 295-300

Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic ... [more ▼]

Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic bone diseases characterised by excessive bone resorption, such as osteoporosis. Most randomised studies in which salcatonin and oral calcium were administered for 1 to 5 years to recently postmenopausal women for the prevention of osteoporosis have shown that bone mineral density or bone content of the lumbar spine increased significantly, compared with a reduction among women receiving calcium only. Prospective studies have shown that salcatonin is effective in the treatment of established osteoporosis, reducing significantly the relative risk of new vertebral fractures. The benefits of salcatonin nasal spray therapy were observed in the majority of women studied, and it has been shown to be an effective alternative for osteoporotic women more than 5 years postmenopausal who refuse estrogens, or for whom estrogens are contraindicated. Finally, in established osteoporosis, nasal calcitonin possesses a potent analgesic effect. The well-demonstrated effects of nasal calcitonin permit it to be considered a well tolerated and efficient approach for prevention and treatment of postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Ostéoporose et beta-thalassémie
Halkin, V.; Francotte-Lempereur, N.; Debrun, A. et al

in Revue Médicale de Liège (1997), 52(3), 138-41

Detailed reference viewed: 15 (2 ULg)
Peer Reviewed
See detailThe role of bisphosphonates in the treatment of osteoporosis
Reginster, Jean-Yves ULg; Halkin, V.; Gosset, Christiane ULg et al

in Drugs of Today (Barcelona, Spain : 1998) (1997), 33

Detailed reference viewed: 8 (0 ULg)